

Form PTO-1449 (modified)

Atty. Docket No.  
UTSC:761USSerial No.  
10/629,329

## List of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
July 29, 2003Group:  
Unknown 1646

## U.S. Patent Documents

See Page 1

## Foreign Patent Documents

See Page 1

## Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
RLi	C1	Bucay <i>et al.</i> , "Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification," <i>Genes Dev.</i> , 12:1260-1268, 1998.
	C2	Darnay <i>et al.</i> , "Activation of NF- $\kappa$ B by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF- $\kappa$ B-inducing kinase," <i>J. Biol. Chem.</i> , 274(12):7724-7731, 1999.
	C3	Darnay <i>et al.</i> , "Characterization of the intracellular domain of receptor activator of NF- $\kappa$ B (RANK)," <i>J. Biol. Chem.</i> , 273(32):20551-20555, 1998.
	C4	Dougall <i>et al.</i> , "RANK is essential for osteoclast and lymph node development," <i>Genes Dev.</i> , 13:2412-2424, 1999.
	C5	Fujikawa <i>et al.</i> , "The human osteoclast precursor circulates in the monocyte fraction," <i>Endocrinol.</i> , 137(9):4058-4060, 1996.
	C6	GenBank Accession No. AB028863
	C7	GenBank Accession No. AF132963
	C8	Hofbauer, "The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption," <i>J. Bone Miner. Res.</i> , 15(1):2-12, 2000.
↓	C9	Ishida <i>et al.</i> , "Protein that makes sense in the Argentine ant," <i>Naturwiss.</i> , 89:505-507, 2002.
RLi	C10	Kong <i>et al.</i> , "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis," <i>Nature</i> , 397:315-323, 1999.

25336774.1

EXAMINER: Ruixiang Li DATE CONSIDERED: 2/21/2005

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

07/27/2003

Atty. Docket No.  
UTSC:761USSerial N .  
10/629,329

List of Patents and Publications for Applicant's

Applicant  
Bryant G. Darnay

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
July 29, 2003Group:  
Unknown 1646

## U.S. Patent Documents

See Page 1

## Foreign Patent Documents

See Page 1

## Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
RLi	C11	Li <i>et al.</i> , "RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism," <i>Proc. Natl. Acad. Sci., USA</i> , 97(4):1566-1571, 2000.
	C12	Mizuno <i>et al.</i> , "Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin," <i>Biochem. Biophys. Res. Commun.</i> , 247:610-615, 1998.
	C13	Okahashi <i>et al.</i> , "Osteoclast differentiation is associated with transient upregulation of cyclin-dependent kinase inhibitors p21WAF1/CIP1 and p27KIP1," <i>J. Cell Biochem.</i> , 80(3):339-345, 2001.
	C14	Pullen <i>et al.</i> , "CD40 signaling through tumor necrosis factor receptor-associated factors (TRAFs)," <i>J. Biol. Chem.</i> , 274:14246-14254, 1999.
↓	C15	Scheven <i>et al.</i> , "In vitro osteoclast generation from different bone marrow fractions, including a highly enriched haematopoietic stem cell population," <i>Nature</i> , 321:79-81, 1986.
RLi	C16	Takayanagi <i>et al.</i> , "Induction and activation of the transcription factor NFATc1 (NAFT2) integrate RANKL signaling in terminal differentiation of osteoclast," <i>Dev. Cell</i> , 3(6):889-901, 2002.

25336774.1

EXAMINER:

Runzhang Lu.

DATE CONSIDERED:

2/1/2015

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.